Key Takeaways

  • A dual-antigen mRNA vaccine (Nipah F-205 from the Malaysia strain plus G from the Bangladesh strain) induced strong antibody and cellular responses in hamsters
  • Vaccinated hamsters showed complete survival against lethal Nipah (both strains) and Hendra challenges
  • The work is preclinical and animal-only; no licensed human vaccine exists for either virus

Two of the world's most feared viruses, one vaccine design

Nipah and Hendra — henipaviruses carried by fruit bats — cause severe brain and lung disease with high case fatality rates, and as the researchers note, no licensed vaccine exists for human use. A study published in Nature Communications on November 19, 2026 reports a vaccine designed to cover all three threats at once.

The team, led by groups at Fudan University and the Wuhan Institute of Virology, used structure-guided design to build an mRNA vaccine delivering two antigens: an engineered Nipah fusion protein (F-205, from the Malaysia strain, stabilized so it cannot fuse cells) and the attachment protein (G, from the Bangladesh strain). Delivered in lipid nanoparticles, the vaccine produced strong neutralizing antibody and cellular immune responses in golden hamsters.

Against lethal challenges, the result was complete survival — against Nipah Malaysia, Nipah Bangladesh and Hendra alike. After Nipah challenge, viral RNA was undetectable in lung, spleen and brain; after Hendra, viral burden was significantly reduced, though not fully cleared.

The honesty beat: this is preclinical, animal-only evidence. Hamster protection is the standard first gate for henipavirus vaccines, not proof of human safety or efficacy, and the road from here to a licensed product is measured in years and human trials that have not begun.

The Twikup Take

Nipah sits on every pandemic-watch list precisely because it combines high lethality with no vaccine and no treatment. A single mRNA shot that sterilized two Nipah strains in animals — using the same platform logic as the COVID vaccines — is exactly the kind of insurance science worth doing before it is needed. The caveat is the calendar: insurance is not the same as a product on a shelf.

Image: Illustrative image.

Sources